Xeljanz, Nouriast priced and set for Japan launch
This article was originally published in Scrip
Executive Summary
The latest reimbursement price listing in Japan will pave the way for the first launch anywhere of two drugs, Kyowa Hakko Kirin's Nouriast (istradefylline) for Parkinson's disease and Zeria's Acofide (acotiamide) for functional dyspepsia.